An investigational, first-in-class agent showed hypothesis-generating promise in symptomatic adults with nonobstructive hypertrophic cardiomyopathy (HCM), a condition lacking in good treatment options, in an early dose-finding study.
The 40 patients, who had been randomly assigned to receive the cardiac myosin inhibitor mavacamten (formerly MYK-461, MyoKardia) for 16 weeks, vs 19 given placebo, usually tolerated the drug well and showed significant improvements in cardiomyopathy-related biomarkers, researchers report in the June2 issue of the Journal of the American College of Cardiology.
Patients on mavacamten showed significant dose-dependent reductions in cardiac troponinI (cTnI), a marker for myocardial injury, and of N-terminal proB-type natriuretic peptide (NT-proBNP), which reflects myocardial wall stress.
Both findings suggest a degree of physiologic improvement on the drug, and it may be important that both biomarkers are prognostic in heart failure and HCM, observe the authors, led by CarolynY. Ho, MD, Brigham and Women's Hospital, Boston.
The phase2 trial, MAVERICK-HCM, wasn't powered to show potential drug effects on clinical outcomes or even functional surrogates, like exercise capacity or NYHA class.
But in an exploratory analysis, treatment with mavacamten appeared to improve symptoms and functional capacity in patients with the most severe disease, as indicated by echocardiographic measures of diastolic function and elevations in cTnI.
"Those people seemed to have some hint of clinical efficacy," Ho told theheart.org| Medscape Cardiology. "It's hypothesis-generating and interesting to think about in terms of who are the best patients to target which patients with nonobstructive HCM may most benefit from mavacamten."
An effective drug therapy for nonobstructive HCM, "has been quite elusive. There's a real unmet need for that cohort." And, in contrast to options for patients with the obstructive form of HCM, "there's no physiological or mechanical target for invasive therapy," she said.
"So people with nonobstructive HCM who are severely symptomatic have really just been adrift without effective therapies."
"The biomarker data are striking and suggest a physiological benefit," write JaneE. Wilcox, MD, and ElizabethM. McNally, MD, PhD, in a linked editorial. "These findings represent a rigorous, well-designed phase2 study that has offered a glimmer of hope in a high-risk nonobstructive HCM population with limited available therapies."
In contrast, "a one-sized approach does not fit all, and high-risk subgroups of an already highly selected population (59 nonobstructive-HCM patients enrolled after screening over 150 patients) may not be reflective of physiology across the entire spectrum of nonobstructive disease," caution the editorialists, from Northwestern University, Chicago.
The main report describes mavacamten as a "small molecule, allosteric inhibitor of cardiac-specific myosin adenosine triphosphatase. It specifically reduces excessive cross-bridging with actin, which is believed to be an important contributor to the pathological hypercontractility associated with HCM." It therefore targets what is believed to be one of HCM's underlying pathophysiologic mechanisms.
The drug is also under development for the obstructive form of HCM, for which it performed favorably in the 251-patient EXPLORER-HCM trial, MyoKardia recently announced along with cursory top line results. Ho is on that trial's steering committee.
The phase3 EXPLORER-HCM trial, the company said, showed a significant benefit from mavacamten for a primary end point reflecting changes in peakVO2 and symptoms, as well as secondary functional, hemodynamic, and quality-of-life end points.
MAVERICK-HCM randomized 19 and 21 patients to receive mavacamten uptitrated to plasma levels of 200ng/mL and 500ng/mL, respectively, and 19 to receive placebo. For entry, they were required to be 18 years or older with nonobstructive HCM with NYHAclass 2 or 3 symptoms, elevated NT-proBNP, increased left ventricular (LV) wall thickness, an LV ejection fraction of at least 55%, and a family history of HCM.
The drug was said to be well tolerated in all patients except five who showed reversible declines in LV ejection fraction to less than 45%. Serious adverse events, which included atrial fibrillation, occurred in 10.3% of mavacamten recipients and 21.1% of those on placebo. Treatment-associated adverse events of any kind, usually mild and self-limiting, were seen in 90% and 68%, respectively. The most common among those receiving mavacamten were palpitations, dizziness, and fatigue, the group reports.
The geometric means for NT-proBNP fell by 53% for those receiving mavacamten and 1% for those on placebo (P= .0005), and for cTnI declined 34% and rose 4%, respectively (P = .009).
"These patients tend to be the most challenging patients to take care of clinically, just because we have so little to offer, other than transplant. So trying to address that unmet need is not going to be met certainly in one step by one trial," Ho told theheart.org| Medscape Cardiology.
"Key will be trying to figure out who best to target, who are those responders, what are their characteristics, and how can we identify that information and be able to treat in a more precise, proactive manner."
MAVERICK-HCM was supported by MyoKardia, which "was involved in the study design and interpretation of the data, analysis, writing of the report, and in the decision to submit the manuscript for publication." Ho discloses consulting for MyoKardia and serving on an advisory board for Ambry Genetics. Disclosures for the other authors are in the report. Wilcox discloses serving as a speaker for and receiving honoraria from Medtronic, serving on an advisory board for Cytokinetics, and serving as a speaker or consultant for Boehringer Ingelheim. McNally discloses serving as a consultant for Amgen, AstraZeneca, Pfizer, Tenaya Therapeutics, Cytokinetics, and Invitae.
J Am Coll Cardiol. 2020;75:2649-2660. Full text, Editorial
Follow Steve Stiles on Twitter: @SteveStiles2. For more from theheart.org| Medscape Cardiology, follow us on Twitter and Facebook.
Read this article:
Mavacamten Phase 2 Results Hopeful in Nonobstructive HCM - Medscape
- Muscular Dystrophy - OrthoInfo - AAOS - December 25th, 2017 [December 25th, 2017]
- Adult Stem Cells - Therapies and Treatments - January 3rd, 2018 [January 3rd, 2018]
- Stem Cell Treatment for Cerebral Palsy Beike Biotechnology - January 22nd, 2018 [January 22nd, 2018]
- Crohns Disease and Ulcerative Colitis - February 6th, 2018 [February 6th, 2018]
- Ulcerative Colitis - Drugs.com - February 6th, 2018 [February 6th, 2018]
- Eczema Symptoms | Causes | Treatments | Types | Triggers - March 2nd, 2018 [March 2nd, 2018]
- Atopic Eczema - Patient - March 12th, 2018 [March 12th, 2018]
- Arnold Schwarzenegger undergoes heart surgery | Film | The ... - April 4th, 2018 [April 4th, 2018]
- Arnold Schwarzenegger Undergoes Emergency Heart Surgery - April 4th, 2018 [April 4th, 2018]
- Cardiac Surgery - University of California, San Francisco ... - April 4th, 2018 [April 4th, 2018]
- Cerebral Palsy Spasticity in Children - Causes, Effects ... - May 6th, 2018 [May 6th, 2018]
- Cardiac catheterization - Mayo Clinic - May 22nd, 2018 [May 22nd, 2018]
- Welcome to the ABG Tutorial - Welcome to Hansen Nursing - May 22nd, 2018 [May 22nd, 2018]
- UKNEQAS for Molecular Genetics - May 23rd, 2018 [May 23rd, 2018]
- Congenital Heart Defects, Simplified - May 23rd, 2018 [May 23rd, 2018]
- Interventional radiology - Wikipedia - May 27th, 2018 [May 27th, 2018]
- Heart Rhythm Abnormalities (Arrhythmias) - NYP.org - May 30th, 2018 [May 30th, 2018]
- Cardiac rhythm abnormalities - symptoms and treatment ... - May 30th, 2018 [May 30th, 2018]
- Pediatric Heart Institute | Children's Hospital Vanderbilt - June 2nd, 2018 [June 2nd, 2018]
- Concentric Remodeling - Cardioserv - June 5th, 2018 [June 5th, 2018]
- Aegean Conferences - June 7th, 2018 [June 7th, 2018]
- 2018 Cardiac Regulatory Mechanisms Conference GRC - June 7th, 2018 [June 7th, 2018]
- Fight Heart Disease - Victor Chang Cardiac Research Institute - June 7th, 2018 [June 7th, 2018]
- NHS Direct Wales - Encyclopaedia : Ulcerative colitis - June 11th, 2018 [June 11th, 2018]
- Cannabis Treatment for Parkinson's Disease Green Rush Daily - June 11th, 2018 [June 11th, 2018]
- Diuretics - Pharmacology - Merck Veterinary Manual - June 18th, 2018 [June 18th, 2018]
- 2018 Multiscale Plant Vascular Biology Conference GRC - June 23rd, 2018 [June 23rd, 2018]
- Cerebral Palsy Treatment | Birth Injury Guide - July 9th, 2018 [July 9th, 2018]
- Division of Pediatric Cardiology | University of Maryland ... - July 11th, 2018 [July 11th, 2018]
- Nuclear Medicine - Molecular Imaging - Nuclear Medicine ... - July 11th, 2018 [July 11th, 2018]
- Blood vessel - Wikipedia - July 12th, 2018 [July 12th, 2018]
- What is Atrial Fibrillation (AF)? - Heart Foundation NZ - July 15th, 2018 [July 15th, 2018]
- EBR Systems, Inc - July 17th, 2018 [July 17th, 2018]
- Coronary artery disease - Symptoms and causes - Mayo Clinic - July 29th, 2018 [July 29th, 2018]
- CV Physiology | Ventricular and Atrial Hypertrophy and ... - July 31st, 2018 [July 31st, 2018]
- Cardiac Surgery Advanced life Support - Home - August 2nd, 2018 [August 2nd, 2018]
- Cardiac Nursing Care: NCP - 5 Nursing Diagnosis for ... - August 2nd, 2018 [August 2nd, 2018]
- Welcome to Hansen Nursing - August 2nd, 2018 [August 2nd, 2018]
- TARA / Innovating predictive cardiac physiology - August 18th, 2018 [August 18th, 2018]
- Board of Directors Summary - Victor Chang Cardiac Research ... - August 18th, 2018 [August 18th, 2018]
- Wound Care - KRMC - September 19th, 2018 [September 19th, 2018]
- Welcome to the ABG Tutorial - Welcome to Hansen - October 13th, 2018 [October 13th, 2018]
- Sudden Death in Dogs - Pet Health Network - October 15th, 2018 [October 15th, 2018]
- gmcheart.com - Cardiovascular Services at Gwinnett Medical ... - November 14th, 2018 [November 14th, 2018]
- Interventional Cardiology | WVU Heart and Vascular Institute - November 21st, 2018 [November 21st, 2018]
- Heart Attack (Myocardial Infarction) | Symptoms and Causes - November 22nd, 2018 [November 22nd, 2018]
- Cerebral Palsy | Boston Children's Hospital - November 27th, 2018 [November 27th, 2018]
- Cerebral Palsy | Cleveland Clinic - November 27th, 2018 [November 27th, 2018]
- Cerebral Palsy - November 27th, 2018 [November 27th, 2018]
- Cerebral Palsy Diagnosis and Treatments | Gillette Children's ... - November 27th, 2018 [November 27th, 2018]
- Cerebral palsy | Genetic and Rare Diseases Information Center ... - November 27th, 2018 [November 27th, 2018]
- Spastic cerebral palsy - Wikipedia - November 27th, 2018 [November 27th, 2018]
- Cerebral Palsy - CHASA - November 27th, 2018 [November 27th, 2018]
- Cerebral Palsy Symptoms & Types - WebMD - November 27th, 2018 [November 27th, 2018]
- Cerebral palsy - NHS - November 27th, 2018 [November 27th, 2018]
- Ventricle (heart) - Wikipedia - December 4th, 2018 [December 4th, 2018]
- Cardiomyopathy - Wikipedia - December 5th, 2018 [December 5th, 2018]
- Cardiomyopathy - British Heart Foundation - December 5th, 2018 [December 5th, 2018]
- Cardiomyopathy | National Heart, Lung, and Blood Institute ... - December 5th, 2018 [December 5th, 2018]
- Community Mental Health Centers - MS Department of Mental ... - December 9th, 2018 [December 9th, 2018]
- Atopic dermatitis (eczema) - Symptoms and causes - Mayo Clinic - December 23rd, 2018 [December 23rd, 2018]
- Dermatitis - Wikipedia - December 23rd, 2018 [December 23rd, 2018]
- Eczema Symptoms & Causes | National Eczema Association - December 23rd, 2018 [December 23rd, 2018]
- Eating too much added sugar increases the risk of dying ... - December 25th, 2018 [December 25th, 2018]
- Heart Diseases & Disorders - December 25th, 2018 [December 25th, 2018]
- 5 Types of Heart Disease Symptoms, Risk Factors, Causes ... - December 25th, 2018 [December 25th, 2018]
- Different heart diseases - World Heart Federation - December 25th, 2018 [December 25th, 2018]
- Cardiovascular disease - Wikipedia - December 25th, 2018 [December 25th, 2018]
- Cardiac arrest - Wikipedia - December 27th, 2018 [December 27th, 2018]
- What Is Arrhythmia? Symptoms, Treatment, Causes & Types - December 27th, 2018 [December 27th, 2018]
- Heart arrhythmia - Wikipedia - December 27th, 2018 [December 27th, 2018]
- The Heart Truth - Lower Heart Disease Risk - December 30th, 2018 [December 30th, 2018]
- What are the different types of heart disease? | Heart ... - December 30th, 2018 [December 30th, 2018]
- Radiofrequency ablation - Wikipedia - January 14th, 2019 [January 14th, 2019]
- Singanitropin HGH 100 IU by Singani Pharma - pharmacomstore.ws - February 9th, 2019 [February 9th, 2019]
- Photosynthesis - Definition, Equation and Products ... - March 6th, 2019 [March 6th, 2019]
- Cardiology Conferences | Cardiology World Congress 2019 ... - March 18th, 2019 [March 18th, 2019]
- 2019 Tissue Repair and Regeneration Conference GRC - April 2nd, 2019 [April 2nd, 2019]
- The SHaRe Cardiomyopathy Registry - April 8th, 2019 [April 8th, 2019]
- Heart arrhythmia - Symptoms and causes - Mayo Clinic - April 20th, 2019 [April 20th, 2019]